BioSpace News Archive

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, is reporting the outcome of a protocol-defined interim analysis

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna.

Palleon Pharmaceuticals today announced that it will present new findings from a study leveraging its HYDRA platform that suggests a link between stromal hypersialylation and immunosuppression activity within the colorectal tumor microenvironment at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place in San Diego.

PharmaCyte Biotech, Inc. provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration for guidance on further development of the technology.

Curative Biotechnology Inc. today announced its nomination to its Board of Directors of Dr. Jeffrey Liebmann.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is pleased to announce initial results from the EVX-01 Phase 2 clinical trial, confirming previous successful Phase 1 findings.

Immunitas Therapeutics (“Immunitas”) today announced it will present the first proof-of-concept data on its second program, a myeloid and B cell modulating anti CLEC2D-Toll-like receptor 9 (TLR9) agonist conjugate, at the Society for Immunotherapy of Cancer’s 38th Annual Meeting.

Xēnix Medical Receives FDA Clearance of SOLACE™ Sacroiliac Fixation System with NANOACTIV™ Nanotechnology.